Abbott Lab: beats consensus in Q1
(CercleFinance.com) - In Q1 2019, Abbott Laboratories reported adjusted EPS of 63 cents, above the consensus and two cents over its previous target range.
The healthcare group's revenues rose by 2% to 7.5 billion dollars, with organic growth also above expectations at 7.1%, driven by double-digit gains from long-term growth drivers, such as FreeStyle Libre, MitraClip and Alinity.
Boosted by this strong start to the year, Abbott confirms that, for FY 2019 it is expecting adjusted EPS of between 3.15 dollars and 3.25 dollars, with the middle of this range representing double-digit growth.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The healthcare group's revenues rose by 2% to 7.5 billion dollars, with organic growth also above expectations at 7.1%, driven by double-digit gains from long-term growth drivers, such as FreeStyle Libre, MitraClip and Alinity.
Boosted by this strong start to the year, Abbott confirms that, for FY 2019 it is expecting adjusted EPS of between 3.15 dollars and 3.25 dollars, with the middle of this range representing double-digit growth.
Copyright (c) 2019 CercleFinance.com. All rights reserved.